Patients' Preferences for Adjunctive Parkinson's Disease Treatments: A Discrete-Choice Experiment.
Parkinson’s
discrete choice
stated preferences
Journal
Patient preference and adherence
ISSN: 1177-889X
Titre abrégé: Patient Prefer Adherence
Pays: New Zealand
ID NLM: 101475748
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
05
2023
accepted:
12
08
2023
medline:
19
9
2023
pubmed:
19
9
2023
entrez:
19
9
2023
Statut:
epublish
Résumé
Several adjunctive medications are available to reduce OFF time between levodopa/carbidopa (LD/CD) doses for people with Parkinson's disease (PD). To explore how individuals with PD balance benefits and burdens when considering adjunctive medications. US adults (30-83 years) with self-reported PD, currently treated with LD/CD, who experienced OFF episodes were recruited through the Fox Insight study to complete a discrete-choice experiment survey. Respondents selected among experimentally designed profiles for hypothetical adjunctive PD treatments that varied in efficacy (additional ON time), potential adverse effects (troublesome dyskinesia, risk of diarrhea, risk of change in bodily fluid color), and dosing frequency or the option "No additional medicine". Data were analyzed with random-parameters logit models. Respondents (N=480) would require ≥60 additional minutes of daily ON time to accept either a 40% risk of change in bodily fluid color or 10 additional minutes with troublesome dyskinesia daily. Respondents would require 40 additional minutes of daily ON time to accept a 10% risk of diarrhea and 22 additional minutes of daily ON time to switch from 1 additional pill each day to 1 pill with each LD/CD dose. On average, respondents preferred adjunctive PD medication over no additional medication. Results predicted that 59.1% of respondents would select a hypothetical treatment profile similar to opicapone, followed by no additional medication (27.5%) and a hypothetical treatment profile similar to entacapone (13.4%). The data collected were based on responses to hypothetical choice profiles in the survey questions. The attributes and levels selected for this study were intended to reflect the characteristics of opicapone and entacapone; attributes associated with other adjunctive therapies were not evaluated. Patients with PD expressed interest in adjunctive treatment to increase ON time and would accept reduced ON time to avoid adverse effects.
Sections du résumé
Background
UNASSIGNED
Several adjunctive medications are available to reduce OFF time between levodopa/carbidopa (LD/CD) doses for people with Parkinson's disease (PD).
Objective
UNASSIGNED
To explore how individuals with PD balance benefits and burdens when considering adjunctive medications.
Methods
UNASSIGNED
US adults (30-83 years) with self-reported PD, currently treated with LD/CD, who experienced OFF episodes were recruited through the Fox Insight study to complete a discrete-choice experiment survey. Respondents selected among experimentally designed profiles for hypothetical adjunctive PD treatments that varied in efficacy (additional ON time), potential adverse effects (troublesome dyskinesia, risk of diarrhea, risk of change in bodily fluid color), and dosing frequency or the option "No additional medicine". Data were analyzed with random-parameters logit models.
Results
UNASSIGNED
Respondents (N=480) would require ≥60 additional minutes of daily ON time to accept either a 40% risk of change in bodily fluid color or 10 additional minutes with troublesome dyskinesia daily. Respondents would require 40 additional minutes of daily ON time to accept a 10% risk of diarrhea and 22 additional minutes of daily ON time to switch from 1 additional pill each day to 1 pill with each LD/CD dose. On average, respondents preferred adjunctive PD medication over no additional medication. Results predicted that 59.1% of respondents would select a hypothetical treatment profile similar to opicapone, followed by no additional medication (27.5%) and a hypothetical treatment profile similar to entacapone (13.4%).
Limitations
UNASSIGNED
The data collected were based on responses to hypothetical choice profiles in the survey questions. The attributes and levels selected for this study were intended to reflect the characteristics of opicapone and entacapone; attributes associated with other adjunctive therapies were not evaluated.
Conclusion
UNASSIGNED
Patients with PD expressed interest in adjunctive treatment to increase ON time and would accept reduced ON time to avoid adverse effects.
Identifiants
pubmed: 37724313
doi: 10.2147/PPA.S420051
pii: 420051
pmc: PMC10505378
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2263-2277Informations de copyright
© 2023 Serbin et al.
Déclaration de conflit d'intérêts
Michael Serbin, Charles Yonan, and Olga Klepitskaya are employees of Neurocrine Biosciences. Carol Mansfield is an employee of RTI Health Solutions, and Colton Leach was an employee of RTI Health Solutions when this research was conducted. Connie Marras is on the steering committee for the Fox Insight study. Margaret Sheehan and Anne Donnelly have nothing to disclose for this work.
Références
Value Health. 2016 Jun;19(4):300-15
pubmed: 27325321
Pharmacoeconomics. 2019 Feb;37(2):201-226
pubmed: 30392040
J Neural Transm (Vienna). 2023 Jun;130(6):847-861
pubmed: 36964457
Expert Rev Neurother. 2021 Sep;21(9):1019-1033
pubmed: 34525893
J Chem Neuroanat. 2020 Jan 26;104:101752
pubmed: 31996329
CNS Neurol Disord Drug Targets. 2017;16(4):425-439
pubmed: 28124620
Neurol Ther. 2023 Apr;12(2):391-424
pubmed: 36633762
J Chem Neuroanat. 2016 Jan;71:41-9
pubmed: 26686287
Neuropsychiatr Dis Treat. 2022 Aug 06;18:1603-1618
pubmed: 35968514
Patient Prefer Adherence. 2021 Jun 01;15:1187-1196
pubmed: 34103902
CNS Drugs. 2022 Mar;36(3):261-282
pubmed: 35217995
J Chem Neuroanat. 2017 Mar;80:1-10
pubmed: 27919828
Ann Neurol. 1997 Nov;42(5):747-55
pubmed: 9392574
Neurochem Res. 2014 Dec;39(12):2527-36
pubmed: 25403619
Acta Neurol Scand. 2014 Oct;130(4):239-47
pubmed: 25186800
Pharmacoeconomics. 2014 Sep;32(9):883-902
pubmed: 25005924
Value Health. 2011 Jun;14(4):403-13
pubmed: 21669364
Neurology. 2004 Mar 23;62(6 Suppl 4):S27-31
pubmed: 15037669
Value Health. 2013 Jan-Feb;16(1):3-13
pubmed: 23337210
Mov Disord. 2021 Oct;36(10):2244-2253
pubmed: 34363424
Health Econ. 2012 Feb;21(2):145-72
pubmed: 22223558
Lancet Neurol. 2016 Feb;15(2):154-165
pubmed: 26725544
NPJ Parkinsons Dis. 2018 Jan 24;4:4
pubmed: 29387783
Qual Life Res. 2016 Jun;25(6):1505-15
pubmed: 26627224
Expert Opin Pharmacother. 2022 Jul;23(10):1123-1128
pubmed: 35373688